SubsidieMeestersMethyltransferase inhibitors for treatment of COVID19
DZNep, an IP-secured drug, effectively treats SARS-CoV-2 by suppressing virus growth and enhancing immunity, with ERC-PoC funding to advance it to clinical trials.
Projectdetails
Introduction
Our IP secured drug DZNep is effective in treating SARS-CoV-2 infections in preclinical disease models.
Mechanism of Action
DZNep uniquely suppresses virus growth, triggers innate immunity, and facilitates tissue regeneration.
Project Goals
The ERC-PoC will enable the transition from preclinical to clinical research.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-6-2022 |
| Einddatum | 30-11-2023 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- TECHNISCHE UNIVERSITAET MUENCHENpenvoerder
Land(en)
Geen landeninformatie beschikbaar
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Hit-to-Lead Development of potent broad-spectrum coronavirus fusion inhibitorsThis project aims to develop and optimize broad-spectrum antiviral drugs targeting the S2 domain of coronaviruses to prevent future outbreaks and enhance antiviral therapy markets. | ERC Proof of... | € 150.000 | 2022 | Details |
Virus Inhibition by siRNA Optimized by NMRThis project aims to develop a novel class of siRNA molecules targeting SARS-CoV-2 variants using structural biology, with potential applications for other pathogenic viruses. | ERC Proof of... | € 150.000 | 2022 | Details |
Antibiotic Lead OptimizationThis project aims to optimize and evaluate a novel DnaN inhibitor, WAM-N17, to develop new antibiotics targeting multidrug-resistant bacteria through compound synthesis and in vivo studies. | ERC Proof of... | € 150.000 | 2023 | Details |
Nanobodies blocking immunosuppressive unexplored proteins from the tumor endothelium to promote anti-tumor immune responseThis project aims to develop novel nanobody therapeutics targeting unexplored immunosuppressive genes in endothelial cells to enhance anti-tumor immunity in non-small cell lung cancer. | ERC Proof of... | € 150.000 | 2025 | Details |
PROposing Action to ConTrol and Impede betacoronaVirus EmergenciesDevelop vaccines and monoclonal antibodies targeting subdominant epitopes of SARS-CoV-2 to ensure broad protection against current and future variants, enhancing global pandemic preparedness. | ERC Advanced... | € 2.498.750 | 2023 | Details |
Hit-to-Lead Development of potent broad-spectrum coronavirus fusion inhibitors
This project aims to develop and optimize broad-spectrum antiviral drugs targeting the S2 domain of coronaviruses to prevent future outbreaks and enhance antiviral therapy markets.
Virus Inhibition by siRNA Optimized by NMR
This project aims to develop a novel class of siRNA molecules targeting SARS-CoV-2 variants using structural biology, with potential applications for other pathogenic viruses.
Antibiotic Lead Optimization
This project aims to optimize and evaluate a novel DnaN inhibitor, WAM-N17, to develop new antibiotics targeting multidrug-resistant bacteria through compound synthesis and in vivo studies.
Nanobodies blocking immunosuppressive unexplored proteins from the tumor endothelium to promote anti-tumor immune response
This project aims to develop novel nanobody therapeutics targeting unexplored immunosuppressive genes in endothelial cells to enhance anti-tumor immunity in non-small cell lung cancer.
PROposing Action to ConTrol and Impede betacoronaVirus Emergencies
Develop vaccines and monoclonal antibodies targeting subdominant epitopes of SARS-CoV-2 to ensure broad protection against current and future variants, enhancing global pandemic preparedness.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Protini pan-Corona antiviralsProtinhi onderzoekt stoffen uit een bibliotheek voor behandelingen tegen dengue en Zika, met potentieel voor COVID-19, om patenten te ondersteunen en partners voor vervolgfinanciering te vinden. | Mkb-innovati... | € 20.000 | 2020 | Details |
Fighting Large-Scale Untreated Infectious Diseases with Innovative TreatmentsMeletios is developing a broad-spectrum oral antiviral that targets cell mechanisms to treat acute viral infections, starting with COVID-19, while also managing immune responses. | EIC Accelerator | € 2.500.000 | 2023 | Details |
First-in-class anti-PVR mAb NTX1088 - a novel oncology drug that unlocks the power of human immune system and revolutionizes cancer careNectin Therapeutics is developing NTX1088, a monoclonal antibody that activates the immune system against cancer, currently in Phase I trials to improve patient outcomes in oncology. | EIC Accelerator | € 2.499.998 | 2024 | Details |
THERAPRODit project richt zich op het ontwikkelen van een behandeling voor West-Nile- en Chikungunya-virusinfecties door innovatieve screening van stoffen, om de virusvermenigvuldiging te stoppen. | Mkb-innovati... | € 163.275 | 2019 | Details |
Developing a novel Parkinson's disease drug using small molecule mimetics of Glial cell line-Derived Neurotrophic Factor (GDNF)GeneCode is developing an oral anti-PD drug that mimics GDNF peptide pathways to restore dopamine neurons and alleviate symptoms in Parkinson's patients, with potential applications for other conditions. | EIC Accelerator | € 1.636.639 | 2024 | Details |
Protini pan-Corona antivirals
Protinhi onderzoekt stoffen uit een bibliotheek voor behandelingen tegen dengue en Zika, met potentieel voor COVID-19, om patenten te ondersteunen en partners voor vervolgfinanciering te vinden.
Fighting Large-Scale Untreated Infectious Diseases with Innovative Treatments
Meletios is developing a broad-spectrum oral antiviral that targets cell mechanisms to treat acute viral infections, starting with COVID-19, while also managing immune responses.
First-in-class anti-PVR mAb NTX1088 - a novel oncology drug that unlocks the power of human immune system and revolutionizes cancer care
Nectin Therapeutics is developing NTX1088, a monoclonal antibody that activates the immune system against cancer, currently in Phase I trials to improve patient outcomes in oncology.
THERAPRO
Dit project richt zich op het ontwikkelen van een behandeling voor West-Nile- en Chikungunya-virusinfecties door innovatieve screening van stoffen, om de virusvermenigvuldiging te stoppen.
Developing a novel Parkinson's disease drug using small molecule mimetics of Glial cell line-Derived Neurotrophic Factor (GDNF)
GeneCode is developing an oral anti-PD drug that mimics GDNF peptide pathways to restore dopamine neurons and alleviate symptoms in Parkinson's patients, with potential applications for other conditions.